Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) DESTINY-PanTumor02 Phase II trial and DESTINY-CRC02 Phase II trial data from ASCO 2023 in patients with HER2-expressing advanced solid tumors.

Ticker(s): AZN, DSKYF

Who's the expert?

Institution: Kaiser Permanente

Gynecologist oncologist at Kaiser Permanente Riverside Medical Center (CA).
Currently treats 10 patients with HER2-expressing advanced solid tumors and treats 75 patients with ovarian cancer and has 2 patients on Elahere.
Very familar with data presented at the ASCO 2023 presentation on AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) DESTINY-PanTumor02 Phase II trial and DESTINY-CRC02 Phase II trial.

Interview Goal

The focus of this interview will be on the recent data presented at ASCO 2023 regarding AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) DESTINY-PanTumor02 Phase II trial and DESTINY-CRC02 Phase II trial in patients with HER2-expressing advanced solid tumors.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.